Efficacy, Tolerability and Adverse Events of Single-Shot Intra-Articular Hyaluronic Acid Injection in Knee Osteoarthritis
Journal Title: Journal of Medical Sciences - Year 2015, Vol 18, Issue 2
Abstract
Objective: The clinical experience with single intra-articular hyaluronic acid injection in knee OA is limited. The aim was to assess the therapeutic efficacy, tolerability and adverse events of single-shot intra-articular hyaluronic acid injection in knee OA. Method: Between February 2008 and December 2010, forty-eight (48) patients (Males=21, Females=27) with OA knees were enrolled in this prospective study. These patients had failed to respond adequately to conservative treatment including analgesics and rehabilitative modalities. The inclusion criteria were (1) Resting visual analog scale pain of >50 mm and (2) Radiographic evidence for osteoarthritis and at least one of the following three characteristics; Age ≥50yrs, Morning stiffness ≤ 30 min in duration and coarse crepitus on motion (as per American College of Rheumatology guidelines 1986). Functional scoring as per WOMAC and VAS for pain at rest and during walking was documented. Patient satisfaction was documented as per Linkert scale. Patients received a single injection of Synvisc-One (consisting of 6 ml hylan G-F 20). The patients were reviewed at 1 month, 3 months and 6 months post- injection with final analysis at 1 year. Use of only paracetamol, when required was allowed for concomitant analgesia. Results: The mean age of the patients was 65 ± 5 years; mean duration of symptoms 5.4 ± 1.5 years and mean body mass index (BMI) 29.1 2 kg/m . Bilateral knees were involved in 69% of patients. Knee swelling and effusion was present in 70% and 31.5 % patients, respectively. All the patients were available at final follow-up. The resting and walking VAS pain significantly improved from baseline after the injection (45 from 70 and 50 from 82, respectively). There was a significant improvement in pain and disability based on the WOMAC scores. Adverse events were recorded and included local pain and swelling, mild redness, and/or effusion in the knee. Based on “Knee Society Score” the overall efficacy was judged as excellent in 55%, satisfactory in 43%, and poor in 2 %. The beneficial effects stayed till 6 months but returned to baseline at last follow up at 1 year. Conclusions: This study confirmed the therapeutic efficacy and safety of single-shot intra-articular injection of hyaluronic acid for the treatment of osteoarthritis of the knee. The pain relief and functional improvement last for up to 6 months. The procedure is tolerated well and associated with very few local adverse events. The need for concomitant analgesia is reduced.
Authors and Affiliations
Shahid Hussain, Abdul Hamid Rather, Asif Qayoom
Keywords
Related Articles
- EP ID EP432563
- DOI -
- Views 42
- Downloads 0
Non-Human Primates as Models for Diabetes Research: A Skeptic Outlook
Apart from numerous parallels, human beings have different evolutionary, physiological and biochemical features when compared to non-human primates. This has particular relevance to our nutrition patterns, stress (and th...
Clinical Trial Regulations In India : Past, Present and Future
Clinical trials are the only way of establishing the safety and efficacy of any new drug before its introduction in the market for human use. Clinical trials (with safeguards) are necessary for the introduction of new dr...
Yield Of Bronchoalveolar Lavage In Suspected Pulmonary TB With Negative Induced-Sputum Smear
Background: Bronchoalveolar lavage (BAL) has been used to recover mycobacterium tuberculosis (MTB) from the respiratory tract of patients with lung infiltrates as nearly 50% of pulmonary tuberculosis (PTB) cases are sput...
Profile of nonsmall cell lung cancer, treatment outcome and quality of life – A retro-prospective analysis
INTRODUCTION: As per Globocan 2012 lung cancer is the most commonly diagnosed cancers worldwide (1.8 million, 13.0% of the total cancer), and the most common cause of cancer deaths. Non small cell lung cancer constitutes...
Denosumab For The Treatment Of Bisphosphonate-Refractory Hypercalcemia Of Malignancy - A Case Report
Hypercalcemia of malignancy caused primarily by tumor-induced bone resorption may lead to renal failure, coma, and death. Patients treated with routine intravenous bisphosphonates may not respond or may relapse on therap...